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Background. We conducted a systematic review to assess the evidence for speciﬁc eﬀects of cannabis on brain
structure and function. The review focuses on the cognitive changes associated with acute and chronic use of the
drug.
Method. We reviewed literature reporting neuroimaging studies of chronic or acute cannabis use published up until
January 2009. The search was conducted using Medline, EMBASE, LILACS and PsycLIT indexing services using the
following key words : cannabis, marijuana, delta-9-tetrahydrocannabinol, THC, cannabidiol, CBD, neuroimaging,
brain imaging, computerized tomography, CT, magnetic resonance, MRI, single photon emission tomography,
SPECT, functional magnetic resonance, fMRI, positron emission tomography, PET, diﬀusion tensor MRI, DTI-MRI,
MRS and spectroscopy.
Results. Sixty-six studies were identiﬁed, of which 41 met the inclusion criteria. Thirty-three were functional
(SPECT/PET/fMRI) and eight structural (volumetric/DTI) imaging studies. The high degree of heterogeneity across
studies precluded a meta-analysis. The functional studies suggest that resting global and prefrontal blood ﬂow are
lower in cannabis users than in controls. The results from the activation studies using a cognitive task are inconsistent
because of the heterogeneity of the methods used. Studies of acute administration of THC or marijuana report
increased resting activity and activation of the frontal and anterior cingulate cortex during cognitive tasks. Only three
of the structural imaging studies found diﬀerences between users and controls.
Conclusions. Functional neuroimaging studies suggest a modulation of global and prefrontal metabolism both
during the resting state and after the administration of THC/marijuana cigarettes. Minimal evidence of major eﬀects
of cannabis on brain structure has been reported.
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Introduction
Marijuana (Cannabis sativa) is the world’s most widely
used illicit drug (Watson et al. 2000 ; Zuardi, 2006). The
principal psychoactive constituent of cannabis is
D9-tetrahydrocannabinol (THC) (Hirst et al. 1998).
Other important components of the plant are canna-
bidiol (CBD), cannabinol (CBN) and cannabigerol
(CBG) (Williamson & Evans, 2000). Except for CBD,
cannabinoids act as agonists at speciﬁc endogenous
cannabinoid receptors, CB1 and CB2 (Pertwee & Ross,
2002). The CB1 receptor is largely expressed in the
central nervous system with the highest concentra-
tions in the basal ganglia, prefrontal cortex, anterior
cingulate cortex (ACC) and hippocampus (Pertwee &
Ross, 2002). CB2 receptors are mainly present in im-
mune cells and peripheral tissues. CBD has weak
partial antagonistic properties at the CB1 receptor. It
inhibits the reuptake and hydrolysis of anandamide,
and exhibits neuroprotective antioxidant activity
(Roser et al. 2008).
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Cannabis intoxication is associated with a large
variety of physiological and cognitive alterations
(Hollister, 1986 ; Hall & Solowij, 1998 ; Lundqvist,
2005). Moreover, use of the drug has been associated
with an increased risk for the onset of schizophrenia,
especially in adolescent users (Arsenault et al. 2004 ;
DeLisi, 2008 ; Schneider, 2008). These eﬀects may be
related to the binding of cannabinoids to CB1 receptors
(Freund et al. 2003). CBD reverses some of the bio-
chemical, physiological and behavioural eﬀects of CB1
receptor agonists, attenuating the anxiogenic eﬀect
of THC (Zuardi et al. 1982).
Neuroimaging has provided powerful tools to
study the in vivo eﬀects of cannabis on brain structure
and function (Volkow et al. 2003 ; Crippa et al. 2005).
These eﬀects can be analysed in experimental settings
following the administration of THC and CBD or in-
directly by comparing subjects with and without a his-
tory of cannabis use. Recent reviews have examined
this topic (Quickfall & Crockford, 2006 ; Chang &
Chronicle, 2007 ; Gonzalez, 2007). However, these re-
views only examined papers published up to 2005
(Quickfall & Crockford, 2006) or 2006 (Chang &
Chronicle, 2007), and their selection criteria have not
been clearly speciﬁed (Chang & Chronicle, 2007 ;
Gonzalez, 2007) or have not been suﬃciently restric-
tive (Quickfall & Crockford, 2006). In present study,
we conducted a systematic review to assess the evi-
dence for speciﬁc eﬀects of cannabis on brain structure
and function, focusing on the cognitive changes
associated with chronic or acute cannabis use. Papers
published up until January 2009 have been included.
Given the large number of variables that might inﬂu-
ence the results of neuroimaging studies, we estab-
lished a comprehensive search strategy and restrictive
set of criteria for selecting articles.
Method
Search strategy
Electronic searches were performed using EMBASE
(1980–January 2009), Medline (1966–January 2009),
PubMed (1966–January 2009), PsycLIT (1974–January
2009) and LILACS (1982–January 2009) databases, ref-
erence searching, and chapters in books on substance
abuse neuroimaging. We used the following key
words: marijuana; cannabis ; delta-9-tetrahydro-
cannabinol, THC; cannabidiol, CBD; neuroimaging;
brain imaging; computerized tomography, CT; mag-
netic resonance, MRI ; single photon emission
tomography, SPECT; functional magnetic resonance,
fMRI; positron emission tomography, PET; diﬀusion
tensor MRI, DTI-MRI ; spectroscopy, MRS. We
included all studies published up until January 2009
without any language restriction.
Selection criteria
Initially we performed a general review of all neuro-
imaging studies that investigated brain structure or
function in relation to cannabis use. Studies were only
included if they met the following criteria. (1) For
studies with a case–control design: inclusion of a
control group of healthy volunteers (participants of
both groups had to be matched for age, sex and
handedness ; users had to be abstinent for at least 12 h
before brain scanning). (2) For studies involving
experimental administration of cannabinoids : use of
a parallel design with healthy controls or cross-over
design; subjects had to be abstinent for cannabinoids
at least 1 week before the experiment, 24 h for alcohol,
and no smoking of tobacco or drinking caﬀeine on the
day of the experiment (Gorelick & Heishman, 2006).
The exclusion criteria were : (1) non-neuroimaging
studies of cannabis use ; and (2) neuroimaging studies
that involved participants <18 years of age, or sub-
jects who had other neurological or psychiatric dis-
orders, or individuals with substance abuse disorders
who were not abstinent or who tested positive for
drugs other than cannabis on urine screening.
When the data from a single subject sample were
reported in separate publications, these were treated
as a single study with multiple independent variables.
Conversely, a publication that reported two forms of
diﬀerent imaging data from the same subjects (e.g.
MRI and PET) or a study examining the same subjects
with two diﬀerent cognitive tasks (e.g. auditory
attention and verbal working memory) were con-
sidered as two studies.
Finally, we deﬁned chronic cannabis users as per-
sons who used cannabis several times a week and
who had done so for at least 2 years. Recreational (or
occasional) cannabis users were deﬁned as persons
who used cannabis sporadically (less than four times a
month) whereas naı¨ve cannabis users or healthy con-
trols were persons who had used cannabis less than
15 times in their lifetime, according to standardized
strict criteria (Crippa et al. 2004).
Recorded variables
Two of the authors extracted the data independently
(A. F. and R. M. S.). When there was no agreement, a
third author ( J. A. C.) reviewed the paper indepen-
dently. The recorded variables for each article were
gender, age, number of joints (cannabis cigarettes)/
week/years of use (to classify subjects as chronic,
recreational or naı¨ve cannabis users), handedness of
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subjects, type of design, exclusion criteria (for neuro-
logical, psychiatric or drug history), interval of
cannabis and other drugs abstinence (as checked by
urine tests), rest/active condition (for functional
imaging studies), type of task performed during func-
tional imaging, blinded design, randomization, doses
of cannabis (percentage of THC of cannabis cigarettes
or mg/mi, of THC intravenous administered or oral
THC (in mg), or oral CBD (in mg), plasma concen-
tration levels, pulse rate, respiratory rate, blood pres-
sure and degree of intoxication. We also recorded all
psychopathological variables, such as ratings of
depersonalization, temporal disintegration, paranoid
symptoms, anxiety or depression. For structural and
functional imaging data, the primary measures of in-
terest were global and regional volume and global and
regional activity [cerebral blood ﬂow (CBF), regional
CBF (rCBF) or blood oxygen level dependent (BOLD)
signal].
Results
Of the 66 studies identiﬁed initially, three were pub-
lished in the 1970s, four in the 1980s, 12 from 1991 to
1999, and 47 between 2000 and 2008. Twenty-ﬁve
studies were eliminated because they did not meet a
priori selection criteria (for excluded studies and
reasons for exclusion, see Fig. 1). The remaining stud-
ies were grouped according to the neuroimaging
technique used (structural/functional), eﬀects of
cannabis use (acute eﬀects of THC/marijuana/CBD
administration/chronic eﬀects of cannabis use) and
testing conditions (resting condition/cognitive task)
(Fig. 1). The studies examined thus comprised: 15
studies involving experimental administration of
THC/marijuana (nine in the resting state and six
during a cognitive task), three studies involving ex-
perimental administration of CBD (one in the resting
state and two during a cognitive task), eight structural
imaging studies evaluating chronic eﬀects of THC
[ﬁve volumetric and three diﬀusion tensor imaging
(DTI) studies] and 17 functional imaging studies on
chronic THC eﬀects (seven in the resting state and 10
during a cognitive task). The reviewed studies in-
cluded a total number of 655 cannabis users and 402
healthy controls.
Because of the heterogeneity in the study design
(case–control/parallel/cross-over) and the methods
used (such as neuroimaging technique) we decided it
would be impractical to perform a meta-analysis.
Moreover, a systematic review without meta-analysis
was chosen for several other reasons : (a) information
needed to compute eﬀect size was not always avail-
able, (b) the methods and extent of detailed infor-
mation to deﬁne regions of interest vary widely in the
studies, preventing accurate comparison, (c) there is a
large diﬀerence in secondary variables across studies
(i.e. gender), and (d) meta-analysis has intrinsic
limitations in estimating negative ﬁndings that do not
get published (the ﬁle drawer problem).
Acute eﬀects (see Table 1)
Acute eﬀects of cannabis on resting state activity
After smoking marijuana cigarettes. Three 133Xe-SPECT
studies examined resting state CBF in chronic or recrea-
tional cannabis users before and after smoking mari-
juana cigarette with controlled THC dose (Table 1).
The studies included in this category described in-
creased regional activity at rest relative to baseline or
marijuana cigarette without THC. An increase in rest-
ing global CBF relative to baseline at 30–60 min fol-
lowing the smoking of a marijuana cigarette with THC
in a proportion of 1.75% or 3.55% was reported in
cannabis users 2 weeks after cessation of use (Mathew
et al. 1992a, Mathew & Wilson, 1993). Increased
activity was also observed in the left temporal lobe
after smoking a marijuana cigarette with 2.2% of THC
(Mathew et al. 1989).
Subjective levels of intoxication (Mathew et al.
1992a, Mathew & Wilson, 1993), dissociative experi-
ences [Temporal Disintegration Inventory (TDI)],
measures of depersonalization [Depersonalization
Inventory (DPI) ; Mathew & Wilson, 1993)] and
measures of confusion (Mathew & Wilson, 1993) have
been correlated with increased global CBF after mari-
juana smoking. Anxiety and confusion in chronic
users following marijuana smoking have been in-
versely correlated with regional activity in several
brain areas after controlling for multiple comparisons
(Mathew et al. 1989). The heart rate correlated posi-
tively with changes in global CBF following the
smoking of a marijuana cigarette (Mathew et al. 1992a)
and inversely with rCBF in the right frontal, bilateral
temporal, parietal and occipital cortices (Mathew et al.
1989). Increased global CBF has also been correlated
with plasma THC levels (Mathew et al. 1992a).
After THC administration. Six studies examined resting
state CBF and metabolism in chronic or recreational
cannabis users before and after the experimental
administration of THC. Four of these studies used
15OH2O-PET (Mathew et al. 1997, 1998, 1999, 2002), one
used 18F-ﬂudeoxyglucose (FDG)-PET (Volkow et al.
1996) and one used [11C]raclopride-PET (Bossong et al.
2009). All but the Volkow et al. study (1996) were
controlled with placebo (Table 1).
All of these studies described increased regional
activity at rest relative to baseline or placebo following
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administration of THC. An increase in resting global
CBF relative to baseline at 30–60 min following THC
administration was reported in cannabis users 2 weeks
after cessation of use (Mathew et al. 1997). Increased
activity was also described in the ACC (Mathew et al.
1997, 1998, 1999, 2002), the insula (Mathew et al. 1997,
1998, 1999, 2002), the prefrontal and orbitofrontal cor-
tices (Volkow et al. 1996) and the cerebellum (Mathew
et al. 1998, 2002). Findings in the basal ganglia, thala-
mus, amygdala and hippocampus have been incon-
sistent, with reports of both increased and reduced
activity in these areas after administration of THC in
Studies included in systematic review (41)
Studies from electronic databases (66)
Failed to meet
inclusion criteria(15)a 
Met exclusion criteria
(13)b
Case/series report
(2)c
Structural (8) Functional (33)
Cannabis users/
controls (17)
Cannabis users/
controls (8)
Excluded studies (25)
Volumetric
(5)
DTI
(3)
Cognitive task
(10)
Resting state
(7)
Experimental administration
THC (7), Marijuana (6), CBD (1), THC or CBD (2)
Associative
memory
task (1)
Verbal
memory
task (1)
Decision
making
task (1)
Motor
task
(1) 
Working
memory
task (2)
Stroop
task
(2)
Attention
task (1)
Finger
tapping
task (1)
Cognitive task
THC/CBD (3), Marijuana (3)
Resting state
THC (6), Marijuana (3), CBD (1)
Motor
Inhibition
task (1)
Self-paced
counting
task (1)
Dichotic
listening
task (2)
Facial
emotion
task (2)
Fig. 1. Flow diagram (selection strategy) of included studies. a No age, sex or handedness matched : Campbell et al. 1971 ; Co et al.
1977 ; Kuehnle et al. 1977 ; Hannerz & Hinmarsh, 1983 ; Aasly et al. 1993 ; Amen & Waugh, 1998 ; Yurgelun-Todd et al. 1998 ;
O’Leary et al. 2000 ; Ward et al. 2002 ; Jacobsen et al. 2004 ; Sneider et al. 2006.No cannabis abstinence : Wiesbeck & Taeschner, 1991 ;
Aasly et al. 1993 ; O’Leary et al. 2000 ; Vorunganti et al. 2001 ; Hermann et al. 2007 ; Nestor et al. 2008 ; Weinstein et al. 2008.
b Psychiatric, other abuse or medical disorders : Campbell et al. 1971 ; Wiesbeck & Taeschner, 1991 ; Yurgelun-Todd et al. 1998 ;
Vorunganti et al. 2001 ; Ward et al. 2002 ; Li et al. 2005 ; Schweinsburg et al. 2005 ; Voytek et al. 2005 ; Jacobsen et al. 2007 ;
Ashtari et al. 2009. No healthy controls : Wiesbeck & Taeschner, 1991 ; Wilson et al. 2000. Others : Volkow et al. 1991 ; Mathew et al.
1992b. c Case/series report : Kuehnle et al. 1977 ; Vorunganti et al. 2001.
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Table 1. Acute eﬀects of cannabis use : functional studies (resting state or with a cognitive task)
Author Method
Users/
controls
Mean age
(S.D.) users/
controls
Users’
type THC dosea
THC
route
Comparison
placebo/
baseline
Image
analysis Condition
Greater volume/
resting blood ﬂow/
BPND/activation
in users
Reduced volume/
resting blood ﬂow/
BPND/activation
in users
Functional (resting state) after marijuana cigarette
Mathew et al.
(1989)
133Xe-SPECT 17/14 28.3 (8.3)/
26.9 (7.5)
C 2.2% s Baseline Scintillation
detector
Resting state L/R frontal blood ﬂow
L temporal blood
ﬂow (chronic users)
Baseline global CBF
(chronic users versus
recreational users)
Mathew et al.
(1992a)
133Xe-SPECT 20/0 25.3 (6.4) R 1.75%/3.55% s Placebo Scintillation
detector
Resting state R frontal and temporal
blood ﬂow
R hemisphere blood ﬂow
Mathew &
Wilson (1993)
133Xe-SPECT 35/0 21.7 (8) R 1.75%/3.55% s Baseline Scintillation
detector
Resting state Global CBF
R frontal blood ﬂow
Functional (resting state) after THC administration
Volkow et al.
(1996)
18F-FDG-PET 8/8 31 (6)/35 (7) C 2 mg i.v. Baseline ROI Resting state PFC blood ﬂow
OFC blood ﬂow
Basal ganglia blood ﬂow
Cerebellar blood ﬂow
Mathew et al.
(1997)
H2
15O-PET 32/0 32.5 (7.6) R 0.15/0.25 mg/
min
i.v. Placebo ROI Resting state Global CBF
R hemisphere blood ﬂow
L/R frontal, insula
and ACC blood ﬂow
Mathew et al.
(1998)
H2
15O-PET 46/0 29.0 (6.1) R 0.15/0.25 mg/
min
i.v. Baseline ROI Resting state L/R ACC blood ﬂow
L/R insula blood ﬂow
L/R cerebellum
blood ﬂow
L/R frontal blood ﬂow
Cerebellar blood ﬂow
Mathew et al.
(1999)
H2
15O-PET 59/0 31.7 (7.5) R 0.15/0.25 mg/
min
i.v. Baseline ROIb Resting state L/R ACC blood ﬂow
R frontal blood ﬂow
R insula blood ﬂow
Basal ganglia, thalamus,
hippocampus and
amygdala blood ﬂow
Mathew et al.
(2002)
H2
15O-PET 47/0 32.0 (8.3) C 0.15/0.25 mg/
min
i.v. Baseline ROIb Resting state R ACC blood ﬂow
R insula blood ﬂow
Ratio of anterior :
posterior blood ﬂow
L/R cerebellum
blood ﬂow
Bossong et al.
(2009)
[11C]Raclopride-
PET
7/0 21.9 (2.7) R 8 mg i Placebo ROIb Resting state BPND in :
Ventral striatum
Precommissural
dorsal putamen
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Table 1 (cont.)
Author Method
Users/
controls
Mean age
(S.D.) users/
controls
Users’
type THC dosea
THC
route
Comparison
placebo/
baseline
Image
analysis Condition
Greater volume/
resting blood ﬂow/
BPND/activation
in users
Reduced volume/
resting blood ﬂow/
BPND/activation
in users
Functional (resting state) after CBD administration
Crippa et al.
(2004)
99mTc-SPECT 0/10 cross-over 29.8 (5.1) N CBD : 400 mg o Placebo Voxel-
based
Resting state L parahippocampal
gyrus blood ﬂow
L amygdala-
hippocampal,
hypothalamus
L posterior cingulate
gyrus blood ﬂow
Functional (cognitive task) after marijuana cigarette
O’Leary et al.
(2002)
H2
15O-PET 12/0 30.5 (8) R 20 mg s Placebo Voxel-basedb Dichotic
listening task
L/R temporal
activation
L ventral frontal
activation
R insula and
putamen activation
L/R cerebellum
activation
L/R frontal
activation
L STG activation
R occipital
activation
O’Leary et al.
(2003)
H2
15O-PET 12 heavy
12
moderate/0
21.7 (1.4) R 20 mg s Baseline Voxel-basedb Self-paced
counting task
Both groups :
ACC, R cerebellar
and L OFC activation
Moderate users :
L/R ventral frontal
lobe, R DLPFC,
R mesial frontal,
R middle temporal and
R parietal activation
Heavy users :
L cerebellar,
L thalamus, L
hippocampal, R frontal
and L STG activation
Both groups :
R occipital, temporal and
frontal activation
O’Leary et al.
(2007)
H2
15O-PET 12/0 23.5 (4.3) R 20 mg s Placebo Voxel-
based
Dichotic
listening task
OFC, ACC, temporal pole,
insula and cerebellum
activation
Visual and auditory
cortices activation
Phan et al.
(2008)
fMRI 0/16 20.8 (2.6) R 7.5 mg o Placebo Voxel-basedb Emotional face
processing
task
R amygdala
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cannabis users (Volkow et al. 1996 ; Mathew et al. 1997,
1999). Following administration of THC, the subjective
level of intoxication was correlated positively with
increases in the anterior/posterior ratio of brain ac-
tivity (Mathew et al. 2002) ; and also activity in the
ACC (Mathew et al. 1997), frontal (Mathew et al. 1997,
1999) and cerebellar cortices (Volkow et al. 1996). TDI
scores have also been negatively correlated with
cerebellar activity (Mathew et al. 1998). Moreover, the
severity of paranoid symptoms following intravenous
THC administration was correlated with the plasma
level of THC (Volkow et al. 1996).
Finally, Bossong et al. 2009 studied the eﬀects of
THC inhalation on [11C]raclopride speciﬁc binding (a
dopamine D2/D3 receptor tracer) in seven healthy
subjects, ﬁnding a reduction in the ventral striatum
and dorsal putamen, which is consistent with an
increase in dopamine levels in these regions.
After CBD administration.One study explored the acute
eﬀect of CBD relative to placebo in a sample of healthy
subjects (Crippa et al. 2004). It showed reduced activity
in medial temporal areas including the left amygdala–
hippocampal complex, extending to the hypothala-
mus, and the left posterior cingulate gyrus and an
increased activity in the left parahippocampal gyrus.
No correlations were observed between subjective
anxiety ratings (the Visual Analogue Mood Scale,
VAMS) and the activity in the brain areas where the
eﬀects of CBD had been predicted a priori, or in the
other unpredicted areas after correction for multiple
comparisons.
Acute eﬀects of cannabis on activation during cognitive
tasks
After smoking marijuana cigarettes. Three PET studies
have examined the acute eﬀect of marijuana cigarettes
with 20 mg of THC on rCBF while subjects were
performing a cognitive task (Table 1).
(a) Attention. Two imaging studies used an attentional
paradigm. O’Leary et al. (2002) evaluated the eﬀects
of marijuana cigarettes with THC on rCBF in regular
cannabis users while performing a dichotic listening
task after 4 days of abstinence. Marijuana with THC
use was associated with increased rCBF (relative to
a cigarette containing marijuana with the THC re-
moved) in the left ventral frontal cortex, right insula,
bilateral temporal pole, ACC, temporal and cerebellar
cortices, whereas there was decreased activity in the
left superior temporal gyrus (O’Leary et al. 2002). In a
subsequent study by the same group, 12 recreational
cannabis users were tested (O’Leary et al. 2007). rCBF
was measured during a tasks requiring attention to left
and right ears in diﬀerent conditions, after smokingFu
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marijuana cigarettes with or without THC, at least a
week apart using a double-blind design. After smok-
ing marijuana cigarettes with THC, there was an in-
crease in rCBF increase in the orbitofrontal cortex,
ACC, temporal pole, insula and cerebellum. On the
contrary, smoking marijuana cigarettes with 20 mg of
THC lowered rCBF in auditory cortices compared to
marijuana cigarette without THC. However, THC did
not alter the normal pattern of attention-related rCBF
asymmetry (greater rCBF in the temporal lobe con-
tralateral to the direction of attention) observed after
subjects smoked marijuana cigarettes without THC.
As attentional neuroanatomical networks are known
to include prefrontal and posterior parietal regions
(Berger & Posner, 2000), these results suggest alter-
ations of the functional anatomical substrate of atten-
tional processes as a consequence of acute cannabis
use.
(b) Motor performance. The above group (O’Leary et al.
2003) has studied the acute eﬀects of smoking mari-
juana cigarettes with 20 mg of THC in heavy and
moderate cannabis users while they performed a self-
paced counting task. In both groups, marijuana with
THC was associated with increased activation in the
cerebellum, the left orbitofrontal cortex and the ACC;
and decreased activation in the right temporal, oc-
cipital and dorsolateral prefrontal cortices. The mag-
nitude of this eﬀect on right ventral and dorsolateral
frontal activation was greater in the moderate than in
the heavy users. Smoking marijuana cigarettes was
also associated with faster response times, which was
related to the change in cerebellar clock activity
(O’Leary et al. 2003).
After THC administration. Three fMRI studies have
examined the acute eﬀect of THC on rCBF while sub-
jects were performing a cognitive task (Table 1). Two
of them (Borgwardt et al. 2008 ; Fusar-Poli et al. 2009)
compared the two main compounds of cannabis, THC
and CBD, controlled by placebo.
(a) Motor response inhibition. Fifteen healthy volunteers
performed a motor inhibition task (Go/No-Go) fol-
lowing oral administration of either 10 mg of THC or
600 mg of CBD or a placebo (Borgwardt et al. 2008).
Relative to the placebo, THC attenuated activation in
the right inferior frontal cortex and the anterior
cingulate gyrus. Conversely, THC was associated with
greater activation in the right hippocampus/para-
hippocampal gyrus, right superior and transverse
temporal gyri and the left posterior cingulated cortex.
These THC-induced changes were not associated with
behavioural eﬀects. By contrast, CBD deactivated
the left temporal cortex and insula. These results
suggested that THC modulates brain function during
response inhibition, whereas the eﬀects of CBD are
evident in other regions that do not mediate this cog-
nitive process.
(b) Emotional processing. Two studies evaluated facial
emotional processing after the administration of can-
nabinoids. Fusar-Poli et al. (2009) evaluated 15 healthy
volunteers on three separate occasions while viewing
faces that implicitly induced diﬀerent emotional pro-
cessing. Each scanning session was preceded by a
single oral dose of 10 mg of THC, 600 mg of CBD or
placebo. After CBD administration, reduced activation
in the amygdala and the anterior and posterior
cingulated cortices was observed while subjects pro-
cessed intensely fearful faces. Conversely, THC
administration modulated activation mainly in the
frontal and parietal regions. Overall, the results sug-
gested that both THC and CBD have eﬀects on neural
response to fearful faces. The second study (Phan et al.
2008) evaluated the eﬀects of 7.5 mg of THC on
amygdala reactivity to social signals of threat (fearful
and angry faces) in 16 recreational cannabis users. The
results suggest that THC signiﬁcantly attenuated
amygdala activation to threatening faces but had no
eﬀect on visual and motor cortex activation.
Non-acute eﬀects (see Table 2)
Structural studies
Eight structural MRI studies have investigated grey
matter volume in chronic cannabis users (Table 2).
Although all of these studies were methodologically
rigorous, three of them did not ﬁnd any signiﬁcant
abnormalities in cannabis users relative to the controls
(Block et al. 2000a ; Tzilos et al. 2005 ; Jager et al. 2007).
Two studies reported structural brain diﬀerences as-
sociated with chronic cannabis use (Matochik et al.
2005 ; Yu¨cel et al. 2008). Matochik et al. (2005) found
that cannabis users had a smaller grey matter volume
than the controls in the right parahippocampal gyrus,
and a larger white matter volume in the contralateral
parahippocampal and fusiform regions. Diﬀerences in
grey matter volume in the right lentiform nucleus,
brain stem, precentral gyrus and right thalamus were
also found. More recently, Yu¨cel et al. (2008) report
bilateral volumetric reductions in the hippocampal
and amygdalar areas in a group of 15 chronic cannabis
users compared with non-users. The volume of the left
hippocampus was inversely associated with the sev-
erity of positive psychotic symptoms, as assessed by
the Scale for the Assessment of Positive Symptoms
(SAPS). Finally, three studies have used DTI to exam-
ine the integrity of white matter tracts in cannabis
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users. Two of them found no diﬀerences between
cannabis users and controls (Gruber & Yurgelun-
Todd, 2005 ; DeLisi et al. 2006). The third study re-
ported a signiﬁcant reduction in mean diﬀusivity, but
no decrease in fractional anisotropy associated with
cannabis use, in the prefrontal section of the corpus
callosum (Arnone et al. 2008). Taken together, these
structural neuroimaging studies provide minimal
evidence of major cannabis eﬀects on brain structure,
both in regional grey matter volumes and in the
integrity of white matter ﬁbres. Subtle alterations may
be easier to detected using functional methods.
Non-acute eﬀects on resting state activity
We included seven case–control studies that com-
pared resting rCBF in cannabis users and healthy
subjects. The imaging methods used were 133Xe-SPECT
(Mathew et al. 1986 ; Tunving et al. 1986 ; Lundqvist
et al. 2001), H2
15O-PET (Block et al. 2000b), [18F]-FDG-
PET (Sevy et al. 2008), [11C]raclopride-PET (Sevy et al.
2008) and dynamic susceptibility contrast (DSC)-MRI
(DSMRI ; Sneider et al. 2008). In a group of nine chronic
cannabis users, assessed within 1 week of drug cess-
ation, Tunving et al. (1986) found a reduction in global
CBF relative to controls that did not correlate with the
duration of cannabis consumption. When four of the
cannabis users were rescanned following a further
abstinence period, an increase in CBF relative to
baseline was observed. Lundqvist et al. (2001) also re-
port lower global CBF in cannabis users than controls
after 5 days of abstinence, and described reduced
rCBF in the right prefrontal and superior frontal
cortex. Block et al. (2000b) report reduced bilateral
cerebellar and ventral prefrontal activity but also
greater right anterior cingulate rCBF in 17 young
chronic marihuana users after 26 h of abstinence.
Mathew et al. (1986) assessed 17 chronic cannabis
users after 12 h of abstinence and found no diﬀerences
in either global or rCBF between cannabis users and
controls. Sneider et al. (2008) examined changes in re-
gional blood volume (rCBV) in a group of 17 healthy
controls and 15 cannabis users. Imaging data were
collected between 6 and 36 h after the subjects’ last
cannabis use, and again after 7 and 28 days of
supervised cannabis abstinence. Their ﬁndings dem-
onstrated that, after 7 days of abstinence, cannabis
users continued to display the same pattern of acti-
vation, characterized by increased rCBV in the right
frontal, bilateral temporal lobes and the cerebellum.
Nevertheless, after 28 days of abstinence only the
temporal and cerebellar areas showed increased ac-
tivity, suggesting that frontal regions begin to nor-
malize with prolonged cannabis abstinence whereas
other regions continue to show altered neural activity.
Finally, a pattern of reduced metabolism in the right
orbitofrontal region and striatum bilaterally was de-
scribed in six subjects with cannabis dependence
compared with six healthy controls. However, there
were no diﬀerences between groups in striatal D2/D3
receptor availability. No correlations between striatal
[11C]raclopride binding potential and glucose metab-
olism were observed (Sevy et al. 2008).
Non-acute eﬀects on activation during cognitive tasks
We included 10 studies that compared regional
activation during performance of a cognitive task in
cannabis users and healthy controls (Table 1).
Memory and attention. Cannabis is known to have ro-
bust eﬀects on short-term episodic memory, which
might be mediated by several mechanisms, including
the inhibition of gamma-aminobutyric acid (GABA),
glutamate and dopamine release (Ranganathan &
D’Souza, 2006). Using 15OH2O-PET, Block et al. (2002)
report that 18 chronic cannabis users (after 26 h of
abstinence) had worst performance with an associat-
ive memory task. This was associated with reduced
activation in the right prefrontal cortex but greater
activation in posterior cerebellum relative to 13
healthy controls. Similar activity in the right dorso-
lateral prefrontal cortex and attenuated bilateral para-
hippocampal activation were reported by Jager et al.
(2007) in 20 chronic cannabis users after 7 days of
abstinence compared with 20 healthy controls. There
were no diﬀerences in task performance between
groups.
Chang et al. (2006) used fMRI to examine visual at-
tention in 24 chronic cannabis users, abstinent for 24 h,
relative to 19 healthy controls. Cannabis users showed
decreased activation in the right prefrontal, medial
and dorsal parietal cortices and medial cerebellar re-
gions. They also showed greater activation in left
frontal subgyral, right parietal subgyral and left
occipital regions. Early age of ﬁrst cannabis use and
greater estimated cumulative use of THC were both
associated with reduced activation in the right pre-
frontal cortex and medial cerebellum, brain regions
that have high concentrations of CB1 receptors.
Working memory. Using fMRI, Kanayama et al. (2004)
measured activation during a spatial working memory
task in 12 heavy cannabis users, after 36 h of absti-
nence, and 10 healthy controls. There were no group
diﬀerences in task performance but the cannabis users
displayed greater activation than controls in the right
superior, middle and inferior frontal gyri, the bilateral
ACC, right precentral and superior temporal gyri, and
in the basal ganglia. Jager et al. (2006) measured acti-
vation during a modiﬁed Sternberg item recognition
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Table 2. Non-acute eﬀects of cannabis use : structural studies (volumetric or DTI) and functional studies (resting state or with a cognitive task)
Author Method
Users/
Controls
Mean age
(S.D.)
users/controls
Users’
type
Image
analysis Condition
Greater volume/resting blood
ﬂow/MD/activation in users
Reduced volume/resting
blood ﬂow/activation in users
Structural (volumetric or DTI)
Block et al.
(2000a)
MRI 18/13 22.3 (0.5)/ C Voxel-based –
22.6 (0.5) ROI
Tzilos et al.
(2005)
MRI 22/26 38.1 (6.2)/ C Voxel-based –
29.5 (8.5) ROI
Matochik
et al. (2005)
MRI 11/8 25.4 (5)/ C Voxel-based – Precentral and R thalamic grey matter R parahippocampal grey matter
29.7 (4.7) ROIa L parahippocampal and fusiform, R
lentiform and brain stem white
matter
L parietal white matter
Jager et al.
(2007)
MRI 20/20 24.5 (5.2)/ C Voxel-based –
23.6 (3.9) ROIa
Gruber et al.
(2005)
DTI 9/9 26 (3.6)/
26.2 (3.1)
Voxel-baseda
ROI
DeLisi et al.
(2006)
DTI 10/10 21.1 (2.9)/ C Voxel-based –
23 (4.4) ROI
Yu¨cel et al.
(2008)
MRI 15/16 38.8 (8.9)/ C Voxel-based – L/R hippocampus
36.4 (9.8) ROI L/R amygdala
Arnone et al.
(2008)
DTI 11/11 25.0(2.9)/ C Voxel-based – Prefrontal regions of corpus callosum
23.3 (2.9)
Functional (resting state)
Tunving et al.
(1986)
133Xe-SPECT 9/9 25 (4.89)/ C Scintillation
detector
Resting state Global CBF
ND
Mathew et al.
(1986)
133Xe-SPECT 17/17 25.5 (8)/ C Scintillation
detector
Resting state
ND
Block et al.
(2000b)
H2
15O-PET 17/12 22.4 (0.5)/
22.6 (0.5)
C Voxel-based Resting state R anterior cingulate blood ﬂow L/R cerebellar and ventral
prefrontal blood ﬂow
Lundqvist
et al. (2001)
133Xe-SPECT 12/14 29.8 (5)/
27.8 (5.2)
C Voxel-based Resting state Global CBF
R PFC blood ﬂow
R superior frontal blood ﬂow
Sneider et al.
(2008)
DSC-MRI 15/17 38.3 (5.6)/
26.4 (3.8)
C ROI Resting state 7 days : R frontal L/R temporal
cerebellum
28 days : L temporal cerebellum
Sevy et al.
(2008)
18F-FDG-PET 6/6 20.0(1.0)/
20.0 (1.0)
C Voxel-based Resting state R OFC
R posterior parietal cortex
L/R putamen
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Sevy et al.
(2008)
[11C]-
raclopride-
PET
6/6 20.0(1.0)/
20.0 (1.0)
C Voxel-based
Volume of
interest
Resting state
Functional (cognitive task)
Block et al.
(2002)
H2
15O-PET 18/13 22.3 (0.5)/
22.6 (0.5)
C Voxel-based Verbal memory L/R PFC activation
ROI
Pillay et al.
(2004)
fMRI 9/16 37 (6)/
29 (10.3)
R Voxel-based Finger
sequencing
L/R SMA activation
L/R ACC activation
Kanayama
et al. (2004)
fMRI 12/10 3 7 (7.4)/
2 7.8 (7.9)
C Voxel-based Spatial working
memory
R inferior and superior frontal gyrus
activation, L/R middle frontal gyrus
activation, R STG activation
R precentral gyrus activation
Bilateral ACC activation, L/R caudate
activation
L/R middle frontal activation
Eldreth et al.
(2004)
H2
15O-PET 11/11 25/29 C Voxel-baseda Stroop L/R hippocampal activation
R paracentral activation
L occipital activation
L DLPFC and ACC activation
R VMPFC and DLPFC
activation
Bolla et al.
(2005)
H2
15O-PET 11/11 26 (21–35)/
31
C Voxel-baseda Iowa Gambling L cerebellar activation
L parietal activation
R OFC activation
R DLPFC activation
Gruber et al.
(2005)
fMRI 9/9 26 (3.6)/
26.2 (3.1)
C Voxel-baseda
ROI
Stroop R DLPFC and L/R ACC activation
Chang et al.
(2006)
fMRI 24/19 27.9 (10.8)/
30.6 (8.0)
C Voxel-baseda
ROI
Visual attention
task
Parietal cortex activation
Occipital cortex activation
R PFC activation
R parietal cortex activation
Cerebellar activation
Jager et al.
(2006)
fMRI 10/10 22.7 (4.2)/
22.8 (2.9)
C Voxel-baseda
ROI
Working
memory
L superior parietal cortex activation
(after practise)
Murphy et al.
(2006)
fMRI 20/25 23 (19–45)/
25 (19–36)
C Voxel-baseda
ROI
Finger-tapping
task
Jager et al.
(2007)
fMRI 20/20 24.5 (5.2)/
23.6 (3.9)
C Voxel-based
ROIa
Associative
memory
L/R Parahippocampal regions
R DLPFC
DTI, Diﬀusion tensor imaging ; S.D., standard deviation ; MRI, magnetic resonance imaging ; SPECT, single photon emission tomography ; PET, positron emission tomography ;
DSC, dynamic susceptibility contrast ; FDG, ﬂudeoxyglucose ; fMRI, functional magnetic resonance imaging ; L, Left hemisphere ; R, right hemisphere ; C, chronic ; R, recreational ;
ROI, region of interest ; CBF, global cerebral blood ﬂow; MD, mean diﬀusivity ; PFC, prefrontal cortex ; DLPFC, dorsolateral prefrontal cortex ; VMPFC, ventromedial prefrontal cortex ;
OFC, orbitofrontal cortex ; ACC, anterior cingulate cortex ; STG, superior temporal gyrus ; SMA, supplementary motor area.
aMultiple comparison correction.
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task in 10 chronic cannabis users, after 1 week of
cessation of use, and 10 controls. Again there were no
task performance diﬀerences between groups but the
controls shown decreased activation in the left su-
perior parietal cortex over repeated trials, which did
not occur with the cannabis users, suggesting a com-
pensatory eﬀect in cannabis users.
Inhibition. Eldreth et al. (2004), using 15OH2O-PET, and
Gruber & Yurgelun-Todd (2005), using fMRI, ex-
amined the degree of inhibitory control during a
Stroop task in chronic cannabis users 25 and 14 days
after cessation of use, respectively. In both studies
cannabis users produced more errors of commission
(failing to inhibit appropriately) than controls and
also showed an altered pattern of brain activation.
Eldreth et al. (2004) found that cannabis users showed
relatively reduced left anterior cingulate, bilateral
dorsolateral prefrontal cortex and right ventromedial
prefrontal cortex activation but greater activation in
the hippocampus bilaterally. Conversely, Gruber &
Yurgelun-Todd (2005) report that nine users showed
greater activation relative to nine controls in the mid-
cingulate cortex and right dorsolateral prefrontal cor-
tex. Consistent with the former study (Eldreth et al.
2004), cannabis users showed reduced anterior cingu-
lated activation. These results suggest that alterations
of cingulate and prefrontal circuits occur in chronic
cannabis users, and leads to the hypothesis that they
recruit alternative brain networks as a compensatory
mechanism.
Decision making. Bolla et al. (2005) report dysfunction
in decision making and associated decreased cortical
activation in 11 cannabis users, after 25 days of can-
nabis abstinence, compared with 11 non-users. Using
15OH2O-PET to study activation during the Iowa
Gambling Task, they demonstrated that cannabis
users not only had a poorer performance than controls
but also showed less activation in the right orbito-
frontal and dorsolateral prefrontal cortex and greater
activation in the left parietal and cerebellar cortex.
Within the cannabis user group, the number of joints
smoked per week was also positively correlated with
activation in the right parahippocampal gyrus but in-
versely correlated with activation in the right orbital
gyrus and cerebellum (Bolla et al. 2005).
Motor performance. Pillay et al. (2004) reported de-
creased activation in the supplementary motor area
and also in the ACC in nine cannabis users, 36 h after
cessation of use, while they performed the ﬁnger se-
quencing task (a measure of ﬁne motor function).
No signiﬁcant correlations between urinary cannabis
level, verbal IQ, attention maintenance [the auditory
Continuous Performance Test (CPT)], reaction time,
memory [the Buschke selective reminding test (BSRT)]
and brain activation were found. On the contrary,
Murphy et al. (2006) found no activation diﬀerences
between 20 chronic cannabis users, after 24 h of cess-
ation of use, and 25 healthy controls during a ﬁnger-
tapping task using fMRI. Both studies were methodo-
logically well-designed and although the cannabis
abstinence period was slightly shorter in the ﬁrst
study, these diﬀerences between them do not fully
explain the divergent results.
Discussion
We found 41 studies suitable for inclusion. The results
of this systematic review have indicated some of the
methodological limitations of the work conducted to
date and demonstrate the high level of heterogeneity
in the ﬁndings of these studies. Some of the functional
studies in the literature had groups that were smaller
than what would be usually regarded as an acceptable
minimum (for PET or SPECT studies 10 subjects and
for fMRI studies 15 subjects). Therefore, studies in-
volving larger samples and incorporating longitudinal
designs may prove useful. The resting state studies
conducted so far did not control spontaneous neural
activity and modulation of the BOLD signal. The
functional studies that used cognitive tasks explored
diﬀerent brain functions, making it diﬃcult to conﬁrm
the results obtained. Thus there is a need for repli-
cation of these ﬁndings. Although the strict inclusion
and exclusion criterion of the protocol is one of this
review’s strengths, it is possible that some of the ex-
cluded articles contain interesting pieces of cannabis
research.
However, several relatively consistent ﬁndings
emerged from this review. Functional neuroimaging
studies suggest that resting global, prefrontal and
ACC blood ﬂow are lower in cannabis users than in
controls (Mathew et al. 1986 ; Tunving et al. 1986 ; Block
et al. 2000b ; Lundqvist et al. 2001 ; Sevy et al. 2008 ;
Sneider et al. 2008). The localization of resting state
diﬀerences between users and controls to these re-
gions is broadly consistent with data from neuro-
psychological studies. Impairments in time estimation,
attention, working memory, cognitive ﬂexibility
(Solowij et al. 2002), decision making (Bechara et al.
2001), and psychomotor speed (Bolla et al. 2002) in
chronic cannabis users are, at least partly, mediated by
these cortical regions. Evidence of eﬀects of THC on
activity in these areas is also consistent with the rela-
tively high concentration of CB1 receptors in the pre-
frontal and cingulated cortex (Freund et al. 2003).
Functional imaging studies that compared acti-
vation in cannabis users and controls during cognitive
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tasks indicate that cannabis users make use of simi-
lar brain areas to controls while performing some
cognitive tasks, although to a lesser degree (Block et al.
2002 ; Eldreth et al. 2004 ; Pillay et al. 2004 ; Bolla et al.
2005 ; Gruber & Yurgelun-Todd, 2005 ; Jager et al. 2006,
2007). Moderately greater task-related activation in
these areas may reﬂect impaired eﬃciency of proces-
sing following cannabis use, such that more activation
is required to maintain normal performance. This
is broadly consistent with the cognitive eﬃciency
hypothesis (Vernon, 1983) that proposes that more
direct connections between task-critical brain regions
may correspond to decreases in task-related neural
activity and improvements in performance (Rypma &
D’Esposito, 2000). The recruitment of additional re-
gions, such as the prefrontal cortex and hippocampus,
also diﬀerentiates users from controls during cognitive
performance (Block et al. 2002 ; Eldreth et al. 2004 ;
Gruber & Yurgelun-Todd, 2005 ; Jager et al. 2007). This
may indicate that increased neurocognitive resources
are required to maintain memory and executive pro-
cesses in this group. However, despite these diﬀer-
ences in brain activity, the level of performance of the
cannabis users was equivalent to that of controls
(Kanayama et al. 2004 ; Jager et al. 2007). In this sense
the brain seems to be capable of some degree of func-
tional reorganization, activating brain regions not
engaged in the non-users to achieve the cognitive de-
mand. This interpretation implies that drug-related
compensatory mechanisms may work, but the real
impact of such alterations in daily users’ life and its
possibility to induce psychiatric disorders are still
controversial.
With regard to structural neuroimaging studies,
only two found signiﬁcant diﬀerences between users
and controls (Matochik et al. 2005; Yu¨cel et al. 2008).
It is likely that volumetric eﬀects would only be ob-
served in heavy long-term users whereas functional
eﬀects would be much easier to detect. Only one DTI
study found diﬀerences in the mean diﬀusivity, sug-
gesting that cannabis users have a small but signiﬁcant
eﬀect on white matter structural integrity (Arnone
et al. 2008).
Finally, more consistent results were evident in
functional imaging studies that examined brain ac-
tivity after the acute experimental administration of
THC or marijuana cigarettes with THC. The most fre-
quent ﬁnding was the increased resting prefrontal,
insular and anterior cingulate activity (Volkow et al.
1996 ; Mathew et al. 1997, 1998, 1999, 2002). Studies that
combined the administration of THC or marijuana
with a cognitive task also described modulated acti-
vation in these regions (O’Leary et al. 2002, 2003, 2007 ;
Borgwardt et al. 2008; Phan et al. 2008 ; Fusar-Poli et al.
2009). The acute administration of CBD has been
associated with increased resting activity in the left
parahippocampus gyrus and a reduction in medial
temporal cortex activity while subjects were proces-
sing intensely fearful faces (Crippa et al. 2004). Of in-
terest, two studies (Borgwardt et al. 2008 ; Fusar-Poli
et al. 2009) showed, for the ﬁrst time, diﬀerent brain
activation associated with THC and CBD in healthy
volunteers, providing new insights into the pharma-
codynamic eﬀects.
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